tamoxifen and glp-1 Receptor Agonist Use Weight Change in Patients With Breast Cancer Tamoxifen - Mechanism of Action
Description
Older GLP-1 medications including liraglutide, dulaglutide, and exenatide have not shown statistically significant increases in hair loss reports
In a mouse model of non-alcoholic fatty liver disease-associated HCC (207), liraglutide prevented HCC progression by modulating blood glucose levels and ameliorating steatosis and inflammation in non-tumorous liver lesions
Follow-up windows were not prespecified, and HbA1c and weight reflect the most recent available clinical measurements with heterogeneous follow-up duration
The text references a GLP-1 prescription
We were extremely impressed to see the final study results
(Link) Komodo Health launches a new enterprise strategy & transformation team for clients
